Hospital Medicine Group Utilizing AI to Enhance Value-Based Care with Dr. John Birkmeyer Sound Physicians TRANSCRIPT

Dr. John Birkmeyer, President of the medical group at Sound Physicians, defines value-based care as an evolution from older managed care models, with closer alignment of incentives for quality of care and cost-effectiveness. Working within the hospital environment, this approach emphasizes standardizing patient-centered care and communication across multiple hospital departments, reducing redundant tests and improving patient outcomes. The use of AI is one way to reduce the administrative burden on physicians, freeing up more time for patient care, a departure from earlier technologies that added to clinicians' workload. John explains, "Sound Physicians is a multi-specialty medical group. It's distinguished in a couple of ways from a lot of the physician groups that your listeners and patients are used to. Number one, it focuses exclusively on specialties that are practiced inside the hospital. So in that context, we work in anesthesia, in the ICU, in hospital medicine, and in the emergency department. And we're different to the extent that we're a very large group. So we're in our 25th year of operations, but we currently run over 400 practices in about the same number of hospitals across most of the states of the US. So in that context, we've learned a lot about what care looks like in different parts of the United States, what things are similar, what things are different, and most importantly, what things work."   "Some of the most important strategies for succeeding with value-based care are things that are very aligned with ensuring not just high quality, but high empathy care to patients. And most importantly, making sure that clinical decisions physicians make in partnership with their patients account for not just scientific evidence but also the values and preferences of patients and their families. More often than not, there's no single right answer for what that patient needs in terms of tests or procedures or other types of care that occur in the hospital. And many of them involve trade-offs between quality of life and length of life, how patients feel about being in the hospital and for how long, how they feel about risk, and what they want to do when they're ultimately discharged from the hospital." #SoundPhysicians #ValueBasedCare #HospitalMedicine #HealthcareInnovation #PatientCare #HealthTech #MedicalGroup #QualityImprovement #HealthcareleaderShip #PhysicianLife #HospitalAdministration soundphysicians.com Listen to the podcast here

Dr. John Birkmeyer, President of the medical group at Sound Physicians, defines value-based care as an evolution from older managed care models, with closer alignment of incentives for quality of care and cost-effectiveness. Working within the hospital environment, this approach emphasizes standardizing patient-centered care and communication across multiple hospital departments, reducing redundant tests and improving patient outcomes. The use of AI is one way to reduce the administrative burden on physicians, freeing up more time for patient care, a departure from earlier technologies that added to clinicians' workload. John explains, "Sound Physicians is a multi-specialty medical group. It's distinguished in a couple of ways from a lot of the physician groups that your listeners and patients are used to. Number one, it focuses exclusively on specialties that are practiced inside the hospital. So in that context, we work in anesthesia, in the ICU, in hospital medicine, and in the emergency department. And we're different to the extent that we're a very large group. So we're in our 25th year of operations, but we currently run over 400 practices in about the same number of hospitals across most of the states of the US. So in that context, we've learned a lot about what care looks like in different parts of the United States, what things are similar, what things are different, and most importantly, what things work."   "Some of the most important strategies for succeeding with value-based care are things that are very aligned with ensuring not just high quality, but high empathy care to patients. And most importantly, making sure that clinical decisions physicians make in partnership with their patients account for not just scientific evidence but also the values and preferences of patients and their families. More often than not, there's no single right answer for what that patient needs in terms of tests or procedures or other types of care that occur in the hospital. And many of them involve trade-offs between quality of life and length of life, how patients feel about being in the hospital and for how long, how they feel about risk, and what they want to do when they're ultimately discharged from the hospital." #SoundPhysicians #ValueBasedCare #HospitalMedicine #HealthcareInnovation #PatientCare #HealthTech #MedicalGroup #QualityImprovement #HealthcareleaderShip #PhysicianLife #HospitalAdministration soundphysicians.com Download the transcript here

Dr. Jim Berenson, Founder of the Institute for Myeloma & Bone Cancer Research and the Berenson Cancer Center, describes the Institute's work, which includes maintaining a large biobank of patient samples that support both its own research and that being conducted by external groups. This biobank is being used to develop new blood markers for faster disease diagnosis, to assess treatment efficacy, and to support drug development for multiple myeloma and other cancers. Real-time monitoring of patient symptoms with a mobile app is capturing critical, often-missed patient data and providing evidence of clinical trial success. Jim explains, "Myeloma is a bone marrow-based cancer of a type of white cell called a plasma cell. These cells normally make a type of protein antibody that helps us fend off infections. And what happens in myeloma is that one of these types of cells goes rogue and takes over the bone marrow.  As a result, these patients make lots and lots of only one type of antibody, and that protein becomes our tumor marker. They can get into trouble with their kidneys, their blood counts, their bones, and their immune system because they can become very compromised both by the disease and the treatment. Therefore, patients can develop frequent infections." "It's diagnosed mainly through blood work, bone marrow examination, and radiologic tests. The latter used to be X-rays, but today it is MRI, CT, or PET scans. The bone marrow test usually demonstrates too many plasma cells that are clonal, meaning they are all of one type. So, usually, the bone marrow plasma cells make up only one-half percent. Myeloma patients have no less than 10% and up to 99% plasma cells, and they are all of one type. They all make one antibody because normally one plasma cell makes one antibody, but this is a clone that's grown a lot in the bone marrow. So, because the bone marrow directly releases proteins into the blood, there's a lot of the myeloma cell-produced antibody in the blood and/or the urine of these patients." "We now have nearly 60,000 bone marrow and blood specimens collected over the last 25 years from our patients, and we collect them in a way that's very systematic. So we obtain blood weekly in the first month, and bone marrow when they undergo the procedure. And then after the first month, the blood is drawn and obtained for research and for the Biobank about every month. And this is a huge resource for not only our own research, which has uncovered two new blood biomarkers through the use of these samples. And we are also able to use the Biobank as a resource for other research groups and companies, whether biotech, pharma, or in vitro diagnostics, to see if they can find a new marker. So we send them a sample, and they can use it for their work." #IMBCR #MultipleMyeloma #HematologyOncology #PrecisionMedicine #PatientMonitoring #DigitalHealth #CancerResearch #Biomarkers #PersonalizedTreatment #QualityOfLife #MedicalInnovation IMBCR.org Listen to the podcast here

Dr. Jim Berenson, Founder of the Institute for Myeloma & Bone Cancer Research and the Berenson Cancer Center, describes the Institute's work, which includes maintaining a large biobank of patient samples that support both its own research and that being conducted by external groups. This biobank is being used to develop new blood markers for faster disease diagnosis, to assess treatment efficacy, and to support drug development for multiple myeloma and other cancers. Real-time monitoring of patient symptoms with a mobile app is capturing critical, often-missed patient data and providing evidence of clinical trial success. Jim explains, "Myeloma is a bone marrow-based cancer of a type of white cell called a plasma cell. These cells normally make a type of protein antibody that helps us fend off infections. And what happens in myeloma is that one of these types of cells goes rogue and takes over the bone marrow.  As a result, these patients make lots and lots of only one type of antibody, and that protein becomes our tumor marker. They can get into trouble with their kidneys, their blood counts, their bones, and their immune system because they can become very compromised both by the disease and the treatment. Therefore, patients can develop frequent infections." "It's diagnosed mainly through blood work, bone marrow examination, and radiologic tests. The latter used to be X-rays, but today it is MRI, CT, or PET scans. The bone marrow test usually demonstrates too many plasma cells that are clonal, meaning they are all of one type. So, usually, the bone marrow plasma cells make up only one-half percent. Myeloma patients have no less than 10% and up to 99% plasma cells, and they are all of one type. They all make one antibody because normally one plasma cell makes one antibody, but this is a clone that's grown a lot in the bone marrow. So, because the bone marrow directly releases proteins into the blood, there's a lot of the myeloma cell-produced antibody in the blood and/or the urine of these patients." "We now have nearly 60,000 bone marrow and blood specimens collected over the last 25 years from our patients, and we collect them in a way that's very systematic. So we obtain blood weekly in the first month, and bone marrow when they undergo the procedure. And then after the first month, the blood is drawn and obtained for research and for the Biobank about every month. And this is a huge resource for not only our own research, which has uncovered two new blood biomarkers through the use of these samples. And we are also able to use the Biobank as a resource for other research groups and companies, whether biotech, pharma, or in vitro diagnostics, to see if they can find a new marker. So we send them a sample, and they can use it for their work." #IMBCR #MultipleMyeloma #HematologyOncology #PrecisionMedicine #PatientMonitoring #DigitalHealth #CancerResearch #Biomarkers #PersonalizedTreatment #QualityOfLife #MedicalInnovation IMBCR.org Download the transcript here

Tom Looby, CEO of Conavi, is focused on developing hybrid intravascular imaging technology that combines two established modalities into a single imaging catheter to provide a comprehensive view of the coronary arteries. This eliminates blind spots when using either intravascular ultrasound (IVUS) or optical coherence tomography (OCT) alone and is driving a shift away from relying solely on traditional angiography toward the use of advanced intravascular imaging to guide coronary procedures. Using AI to analyze dual-stream co-registered data allows interventional cardiologists to more accurately assess lesions, determine the appropriate stent size, and ensure proper placement, thereby reducing cardiac death and blood clots around stents. Tim explains, "So our technology is an imaging catheter. We're unique in that we combine two imaging modalities that are already well established in the market. But because each of them has blind spots, by combining them into a single catheter, we remove those blind spots, and we think we produce the best imaging catheter to help guide coronary interventions."   "It is well known that these strengths and weaknesses occur in both ultrasound and optical imaging. But to set the stage, this is a trend happening in the marketplace. There are four million angioplasty stenting procedures performed each year, and most of them rely solely on traditional angiography. Most of your audience probably knows that angiography is an X-ray that uses a contrast agent, so you're seeing the vasculature around the heart through a secondary image. The detailed view inside the blood vessels is limited when using only angiography, which has restricted the types of procedures doctors have been able to perform over time. Recognizing that intravascular ultrasound, sometimes called IVUS, and separately, OCT—short for optical coherence tomography—were developed independently to examine inside the blood vessel." #Conavi #CardiovascularImaging #InterventionalCardiology #MedicalDevice #HeartHealth #Innovation #IVUS #OCT #AIinHealthcare #CardiacIntervention #HealthTech #Medtech #Cardiology #HybridImaging Conavi.com Listen to the podcast here  

Tom Looby, CEO of Conavi, is focused on developing hybrid intravascular imaging technology that combines two established modalities into a single imaging catheter to provide a comprehensive view of the coronary arteries. This eliminates blind spots when using either intravascular ultrasound (IVUS) or optical coherence tomography (OCT) alone and is driving a shift away from relying solely on traditional angiography toward the use of advanced intravascular imaging to guide coronary procedures. Using AI to analyze dual-stream co-registered data allows interventional cardiologists to more accurately assess lesions, determine the appropriate stent size, and ensure proper placement, thereby reducing cardiac death and blood clots around stents. Tim explains, "So our technology is an imaging catheter. We're unique in that we combine two imaging modalities that are already well established in the market. But because each of them has blind spots, by combining them into a single catheter, we remove those blind spots, and we think we produce the best imaging catheter to help guide coronary interventions."   "It is well known that these strengths and weaknesses occur in both ultrasound and optical imaging. But to set the stage, this is a trend happening in the marketplace. There are four million angioplasty stenting procedures performed each year, and most of them rely solely on traditional angiography. Most of your audience probably knows that angiography is an X-ray that uses a contrast agent, so you're seeing the vasculature around the heart through a secondary image. The detailed view inside the blood vessels is limited when using only angiography, which has restricted the types of procedures doctors have been able to perform over time. Recognizing that intravascular ultrasound, sometimes called IVUS, and separately, OCT—short for optical coherence tomography—were developed independently to examine inside the blood vessel." #Conavi #CardiovascularImaging #InterventionalCardiology #MedicalDevice #HeartHealth #Innovation #IVUS #OCT #AIinHealthcare #CardiacIntervention #HealthTech #Medtech #Cardiology #HybridImaging Conavi.com Download the transcript here  

Theresa Lyons, CEO and Founder of Navigating AWEtism, is providing parents with current, accurate information about autism to help them focus on manageable issues for their child. She strongly cautions about information about autism from social media, which is often over-generalized and incorrect. Autism spectrum disorder presents a wide range of behaviors from mild communication difficulties to complex challenges requiring lifelong care, and Theresa advocates for an individual approach, including lab testing, before choosing a treatment plan. Theresa explains, "What we strive to do is educate parents on the cutting-edge information of autism so that they can make the best decisions for their kids. All too often, parents and I, including myself, are autism parents. We get information that is 20 to 30 years old. So it's really important to make decisions for your child's future based on quality information."   "So autism is a spectrum, and we can talk about one end of the spectrum. A child might be speaking, but they might have difficulty having a back-and-forth conversation. They might be very limited in what they're talking about. Let's say maybe they have a huge interest in trains, and you can talk to this child about trains, but then if you try to have a conversation about the weather, your sneakers, or the beach, something you like to do, then that's where conversation doesn't happen at all. Kids on that end of the spectrum can dress themselves, and they can feed themselves. And when they get older, they will go across the street and potentially drive a car. So that's one end of the spectrum. And then on the other end is more profound autism. And those are kids who might not ever dress themselves or might not have the ability to cut their food ever." #NavigatingAWEtism #AWEtism #Autism #AutismSpectrum #Pediatrics #Healthcare #EvidenceBasedMedicine #Neurodevelopment #FamilyCenteredCare #HealthcareProviders #Misinformation #QualityCare AWEtism.net Listen to the podcast here 

Theresa Lyons, CEO and Founder of Navigating AWEtism, is providing parents with current, accurate information about autism to help them focus on manageable issues for their child. She strongly cautions about information about autism from social media, which is often over-generalized and incorrect. Autism spectrum disorder presents a wide range of behaviors from mild communication difficulties to complex challenges requiring lifelong care, and Theresa advocates for an individual approach, including lab testing, before choosing a treatment plan. Theresa explains, "What we strive to do is educate parents on the cutting-edge information of autism so that they can make the best decisions for their kids. All too often, parents and I, including myself, are autism parents. We get information that is 20 to 30 years old. So it's really important to make decisions for your child's future based on quality information."   "So autism is a spectrum, and we can talk about one end of the spectrum. A child might be speaking, but they might have difficulty having a back-and-forth conversation. They might be very limited in what they're talking about. Let's say maybe they have a huge interest in trains, and you can talk to this child about trains, but then if you try to have a conversation about the weather, your sneakers, or the beach, something you like to do, then that's where conversation doesn't happen at all. Kids on that end of the spectrum can dress themselves, and they can feed themselves. And when they get older, they will go across the street and potentially drive a car. So that's one end of the spectrum. And then on the other end is more profound autism. And those are kids who might not ever dress themselves or might not have the ability to cut their food ever." #NavigatingAWEtism #AWEtism #Autism #AutismSpectrum #Pediatrics #Healthcare #EvidenceBasedMedicine #Neurodevelopment #FamilyCenteredCare #HealthcareProviders #Misinformation #QualityCare AWEtism.net Download the transcript here 

Lori Runion, a director at Resultant, identifies inadequate scheduling and related staffing unpredictability as a central cause of clinician burnout. Healthcare organizations traditionally rely on historical averages for scheduling, often resulting in a mismatch between patient demand and clinician capacity. Breaking down data silos and using analytics and AI to create predictive staffing models can help forecast demand, anticipate seasonal spikes, and enable proactive staffing to reduce clinician burnout. Lori explains, " From my perspective, burnout is driven at the operational level. To say it most simply, I think that burnout is driven by unpredictability, specifically, what I want to talk a little bit about, predictive staffing. And so, when we think about staffing, the unpredictability and misalignment between patient demand and staffing capacity are really what's driving it. So I don't think it's a lack of resilience. I don't think it's necessarily that there are gaps in care, but there are constant coverage gaps and volatility in the workload. And so I think it's ultimately driven by that mismatch when patient demand and clinician capacity are misaligned. I think that healthcare is traditionally staffed based on historical averages rather than dynamic demand or patterns, and that's what creates the unpredictable shifts and last-minute schedule changes that lead to overextension and exhaustion, which drive burnout."   "So, for example, you think about your EHR, which includes your demand, your patient medical record, and you have a scheduling system that shows available capacity, and you may have claims data that shows utilization patterns or other things. So when they are only looking at one system, they have some blind spots. And so I think that if they're looking at connected systems and pulling all that data together to identify patterns and really see the full picture, that's where they can align patient demand with staffing capacity." #Resultant #HealthcareBurnout #PatientSafety #HealthcareLeadership #PredictiveAnalytics #HealthcareData #WorkforceOptimization#ClinicianBurnout #HealthcareAnalytics #PredictiveStaffing #HealthcareIT #DataDriven #PatientCare #HealthcareLeadership #AIinHealthcare #WorkforceOptimization #HealthcareInnovation resultant.com  Listen to the podcast here

Lori Runion, a director at Resultant, identifies inadequate scheduling and related staffing unpredictability as a central cause of clinician burnout. Healthcare organizations traditionally rely on historical averages for scheduling, often resulting in a mismatch between patient demand and clinician capacity. Breaking down data silos and using analytics and AI to create predictive staffing models can help forecast demand, anticipate seasonal spikes, and enable proactive staffing to reduce clinician burnout. Lori explains, " From my perspective, burnout is driven at the operational level. To say it most simply, I think that burnout is driven by unpredictability, specifically, what I want to talk a little bit about, predictive staffing. And so, when we think about staffing, the unpredictability and misalignment between patient demand and staffing capacity are really what's driving it. So I don't think it's a lack of resilience. I don't think it's necessarily that there are gaps in care, but there are constant coverage gaps and volatility in the workload. And so I think it's ultimately driven by that mismatch when patient demand and clinician capacity are misaligned. I think that healthcare is traditionally staffed based on historical averages rather than dynamic demand or patterns, and that's what creates the unpredictable shifts and last-minute schedule changes that lead to overextension and exhaustion, which drive burnout."   "So, for example, you think about your EHR, which includes your demand, your patient medical record, and you have a scheduling system that shows available capacity, and you may have claims data that shows utilization patterns or other things. So when they are only looking at one system, they have some blind spots. And so I think that if they're looking at connected systems and pulling all that data together to identify patterns and really see the full picture, that's where they can align patient demand with staffing capacity." #Resultant #HealthcareBurnout #PatientSafety #HealthcareLeadership #PredictiveAnalytics #HealthcareData #WorkforceOptimization#ClinicianBurnout #HealthcareAnalytics #PredictiveStaffing #HealthcareIT #DataDriven #PatientCare #HealthcareLeadership #AIinHealthcare #WorkforceOptimization #HealthcareInnovation resultant.com Download the transcript here